H. Lee Moffitt Cancer Center & Research Institute


Standort der Organisation:
Tampa, FL, Vereinigte Staaten von Amerika (USA)

Publikationen in Kooperation mit FAU-Wissenschaftern

Go to first page Go to previous page 1 von 2 Go to next page Go to last page
Buckley, M.A., Woods, N.T., Tyrer, J.P., Mendoza-Fandino, G., Lawrenson, K., Hazelett, D.J.,... Freedman, M.L. (2019). Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. Cancer Research, 79(3). https://dx.doi.org/10.1158/0008-5472.CAN-17-3864
Yang, Y., Wu, L., Shu, X., Lu, Y., Shu, X.-O., Cai, Q.,... Long, J. (2019). Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 79(3). https://dx.doi.org/10.1158/0008-5472.CAN-18-2726
Awadalla, M., Golden, D.L.A., Mahmood, S.S., Alvi, R.M., Mercaldo, N.D., Hassan, M.Z.O.,... Neilan, T.G. (2019). Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer, 7. https://dx.doi.org/10.1186/s40425-019-0535-y
Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E.,... Singh, S. (2018). Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.
Yao, J.C., Yao, J.C., Fazio, N., Li, D., Pavel, M.E., Strosberg, J.,... Singh, S. (2018). ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment. (pp. 218-218).
O'Mara, T.A., Glubb, D.M., Amant, F., Annibali, D., Ashton, K., Attia, J.,... Thompson, D.J. (2018). Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 9(1). https://dx.doi.org/10.1038/s41467-018-05427-7
Mahmood, S.S., Fradley, M.G., Cohen, J.V., Nohria, A., Reynolds, K.L., Heinzerling, L.,... Neilan, T.G. (2018). Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 71(16), 1755-1764. https://dx.doi.org/10.1016/j.jacc.2018.02.037
Fazio, N., Carnaghi, C., Buzzoni, R., Valle, J., Valle, J., Herbst, F.,... Yao, J.C. (2018). Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 211-211).
Kelemen, L.E., Earp, M., Fridley, B.L., Chenevix-Trench, G., Fasching, P.A., Beckmann, M.,... Berchuck, A. (2018). rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 19(9). https://dx.doi.org/10.3390/ijms19092473
Chan, D.L., Yao, J.C., Carnaghi, C., Buzzoni, R., Herbst, F., Herbst, F.,... Singh, S. (2018). Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 151-151).
Earp, M., Tyrer, J.P., Winham, S.J., Lin, H.-Y., Chornokur, G., Dennis, J.,... Phelan, C.M. (2018). Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 13(7). https://dx.doi.org/10.1371/journal.pone.0197561
Shimelis, H., Mesman, R.L.S., Von Nicolai, C., Ehlen, A., Guidugli, L., Martin, C.,... Couch, F.J. (2017). BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 77(11), 2789-2799. https://dx.doi.org/10.1158/0008-5472.CAN-16-2568
Goode, E.L., Block, M.S., Kalli, K.R., Vierkant, R.A., Chen, W., Fogarty, Z.C.,... Ramus, S.J. (2017). Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 3(12). https://dx.doi.org/10.1001/jamaoncol.2017.3290
Kar, S.P., Adler, E., Tyrer, J., Hazelett, D., Anton-Culver, H., Bandera, E.V.,... Lawrenson, K. (2017). Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 116(4), 524-535. https://dx.doi.org/10.1038/bjc.2016.426
Pavel, M.E., Singh, S., Strosberg, J.R., Bubuteishvili-Pacaud, L., Degtyarev, E., Neary, M.P.,... Yao, J.C. (2017). Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 18(10), 1411-1422. https://dx.doi.org/10.1016/S1470-2045(17)30471-0
Buzzoni, R., Carnaghi, C., Strosberg, J., Fazio, N., Singh, S., Herbst, F.,... Pommier, R. (2017). Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Oncotargets and Therapy, 10, 5013-5030. https://dx.doi.org/10.2147/OTT.S142087
Zimmer, L., Apuri, S., Eroglu, Z., Kottschade, L.A., Forschner, A., Gutzmer, R.,... Khushalani, N.I. (2017). Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. European journal of cancer, 75, 47-55. https://dx.doi.org/10.1016/j.ejca.2017.01.009
Dixon, S.C., Nagle, C.M., Thrift, A.P., Pharoah, P.D.P., Pearce, C.L., Zheng, W.,... Webb, P.M. (2016). Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 45(3), 884-95. https://dx.doi.org/10.1093/ije/dyw158
Cuellar-Partida, G., Lu, Y., Dixon, S.C., Fasching, P.A., Hein, A., Burghaus, S.,... Macgregor, S. (2016). Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human genetics, 135(7), 741-56. https://dx.doi.org/10.1007/s00439-016-1663-9
Hampras, S.S., Sucheston-Campbell, L.E., Cannioto, R., Chang-Claude, J., Modugno, F., Doerk, T.,... Moysich, K.B. (2016). Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget. https://dx.doi.org/10.18632/oncotarget.10215

Zuletzt aktualisiert 2016-30-04 um 08:14